Evidence map›Paper›PMID 36407462›Full record

ArticleFrontiers in cardiovascular medicine2022

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins.

Sarah Leatherman, Ryan Ferguson, Cynthia Hau, Kelly Harrington, Craig Granowitz, Sephy Philip, Peter Paul Toth, Deepak Bhatt, William Boden

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Sarah LeathermanVA Boston Healthcare System, Veterans Health Administration, United States Department of Veterans Affairs, Boston, MA, United States.
Ryan FergusonVA Boston Healthcare System, Veterans Health Administration, United States Department of Veterans Affairs, Boston, MA, United States.
Cynthia HauVA Boston Healthcare System, Veterans Health Administration, United States Department of Veterans Affairs, Boston, MA, United States.
Kelly HarringtonVA Boston Healthcare System, Veterans Health Administration, United States Department of Veterans Affairs, Boston, MA, United States.
Craig GranowitzLexicon Pharmaceuticals, The Woodlands, TX, United States.
Sephy PhilipAmarin Pharma Inc., Bridgewater, MA, United States.
Peter Paul TothCGH Medical Center, Sterling, IL, United States.
Deepak BhattBrigham and Women's Hospital Heart and Vascular Center, Boston, MA, United States.
William BodenVA Boston Healthcare System, Veterans Health Administration, United States Department of Veterans Affairs, Boston, MA, United States.
United States Department of Veterans Affairs · USVA Boston Healthcare System · USAmarin (United States) · USBoston University · USBrigham and Women's Hospital · USCGH Medical Center · USLexicon Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent studies have demonstrated a causal role for elevated triglycerides (TG) in incident cardiovascular (CV) events in patients with established coronary heart disease (CHD) and those with CV risk factors alone, particularly diabetes. Objective: Using a large cohort of U.S. veterans with statin-controlled LDL-C levels (40-100 mg/dL), we explored residual CV risk among patients with elevated baseline TG levels (150-499 mg/dL) vs. those with normal TG levels (<150 mg/dL). Methods: We identified veterans receiving a statin but not a TG-lowering agent from the VA electronic health records database, from 2010 to 2015. We compared composite CV event rates (MI, stroke, unstable angina, coronary revascularization, and CV death) between the elevated TG and normal TG groups. We stratified the study cohort according to 3 CV risk groups: (1) no diabetes and no prior CV event, (2) diabetes and no prior CV event, and (3) prior CV event. We calculated crude event rates, rate ratios, and event rate ratios adjusted for age, sex, systolic blood pressure, estimated glomerular filtration rate, and weight. Results: The cohort included 396,189 veterans (predominantly male and white) of whom 109,195 (28%) had elevated TG levels. Those with elevated TG were younger (age 73 vs. 77 years) and had a higher body mass index (31.3 vs. 28.3 Kg/M Conclusion: Those with elevated TG levels and well-controlled LDL-C on statins showed a modest increase in CV events compared to those with normal TG. Elevated TG levels were associated with increased CV events in patients with established CV disease and with diabetes only, suggesting that elevated TG levels are associated with a similar degree of residual risk in high-risk primary prevention and secondary prevention settings.

Indexed as

cardiovascular deathcardiovascular eventslow-density lipoproteinresidual risktriglyceride

Identifiers

PMID36407462
PMCPMC9673755
OpenAlexW4308333224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.